ORAL AND INTRAVENOUS DISPOSITION OF CYCLOSPORINE IN PSORIATIC PATIENTS

被引：8

作者：

GALLA, F

MARZOCCHI, V

CROATTINO, L

POZ, D

BARALDO, M

FURLANUT, M

机构：

[1] UNIV UDINE,DEPT SPECIAL PHARMACOL,I-33100 UDINE,ITALY

[2] S MARIA MISERICORDIA HOSP,DERMATOL UNIT,UDINE,ITALY

来源：

THERAPEUTIC DRUG MONITORING | 1995年 / 17卷 / 03期

关键词：

PSORIASIS; CYCLOSPORINE; DISPOSITION;

D O I：

10.1097/00007691-199506000-00014

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

After informed consent was obtained and with the approval of the Local Ethical Committee, cyclosporine A (CsA) kinetics was studied in 63 psoriatic patients by giving them 2.5 mg/kg CsA orally. In order to calculate oral bioavailability, F, 22 patients were given the same dose i.v. Values of the calculated kinetic parameters were oral F = 22-63%; half-life, t(1/2 beta) = 11.05-13.70 h; volume of distribution, V-d, = 4.00-5.02/L/kg; total body clearance, Cl, = 4.25-4.14 ml/min/kg. The area under the blood concentration time curve was more closely related to the dose (r = 0.66) than were trough levels (r = 0.52). No significant relationship was observed between the kinetic parameters studied and the age of the patient.

引用

页码：302 / 304

页数：3

共 12 条

[1]

Mueller W., Herrman B., Cyclosporine for psoriasis, N Engl J Med, 301, (1979)

[2]

Ptachcinski R.J., Venkataramanan R., Rosenthal J.T., Burckart G.J., Taylor R.J., Cyclosporine kinetics in renal transplantation, Clin Pharmacol Ther, 38, pp. 296-300, (1985)

[3]

Venkataraman R., Ptachcinski R.J., Burchart G.J., Cyclosporine pharmacokinetics in heart transplant patients, Transplant Proc, 18, pp. 768-770, (1986)

[4]

Yee G.C., Recent advances in Cyclosporine pharmacokinetics, Pharmacotherapy, 11, pp. 1305-1345, (1991)

[5]

Wang P.P., Simpson E., Meucci V., Morrison M., Lunetta S., Cyclosporine monitoring by fluorescence polarization immunoassay, Clin Biochem, 24, pp. 55-58, (1991)

[6]

Furlanut M., Montanari G., Perosa A., Velussi C., Forgione A., Palatini P., Absorption and disposition kinetics of flunox-aprofen and benoxaprofen in healthy volunteers, Int J Clin PharmRes, 3, pp. 165-170, (1985)

[7]

Beukers R., De Dave S., Van Den Berg J., Schalm S.W., Oral pharmacokinetics of cyclosporin in patients with primary biliary cirrhosis and patients with skin diseases, Aliment Pharmacol Ther, 6, pp. 459-468, (1992)

[8]

Ptachcinski R.J., Venkataramanan R., Buckart G.J., Clinical Pharmacokinetics of Cyclosporin, Clin Pharmacokinet, 11, pp. 107-132, (1986)

[9]

Fahr A., Cyclosporin Clinical Pharmacokinetics, Clin Pharmacokinet, 24, pp. 472-495, (1993)

[10]

Lindholm A., Zachariae H., Reitamo S., Is cyclosporine blood concentration monitoring necessary in patients treated for severe chronic plaque form psoriasis?, Transplant Proc, 22, pp. 1293-1295, (1990)

← 1 2 →